Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Milan Vošmik, Radek Spisek, Vladimír Koucký, Kamila Hladíková, Miroslav Hodek, Petr Čelakovský, Hana Vošmiková, Jan Laco, Ales Ryska, Michal Zábrodský, Viktor Chrobok, Marek Grega, Anna Fialová, Kateřina Rozkošová, Jan Bouček
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-16 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Standard treatment of oropharyngeal squamous cell carcinoma (OPSCC) is associated with high morbidity, whereas immunotherapeutic approaches using PD-1:PD-L1 checkpoint blockade only show moderate response rates in OPSCC patients. Therefore
Autor:
Sonali Jindal, Hong Chen, Christopher J. Logothetis, Ana Aparicio, Rebecca S. S. Tidwell, Paul G. Corn, Padmanee Sharma, Bilal A. Siddiqui, Ashwin Varma, James P. Allison, Sumit K. Subudhi, Shalini S. Yadav, Sreyashi Basu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundImmune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein
Autor:
Eirini Pectasides, Sarah Derks, Charles S. Fuchs, Megan E. Cavanaugh, Peter C. Enzinger, Anuj K. Patel, Amanda J. Rode, Douglas A. Rubinson, Adam J. Bass, Bridget Fitzpatrick, Lauren K. Brais, Nadine Jackson McCleary, Mariano Severgnini, Patrick H. Lizotte, Fahire G Akarca, Jeffrey W. Clark, Leonie K. de Klerk, Melissa G Jean, Matthew Nazzaro, Jeremy Augustin, Mohamed Uduman, James M. Cleary, Hui Zheng, Nihal Raman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 9 (2021)
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 9(9):e002472. BioMed Central
de Klerk, L K, Patel, A K, Derks, S, Pectasides, E, Augustin, J, Uduman, M, Raman, N, Akarca, F G, McCleary, N J, Cleary, J M, Rubinson, D A, Clark, J W, Fitzpatrick, B, Brais, L K, Cavanaugh, M E, Rode, A J, Jean, M G, Lizotte, P H, Nazzaro, M J, Severgnini, M, Zheng, H, Fuchs, C S, Enzinger, P C & Bass, A J 2021, ' Phase II study of pembrolizumab in refractory esophageal cancer with correlates of response and survival ', Journal for Immunotherapy of Cancer, vol. 9, no. 9, e002472 . https://doi.org/10.1136/jitc-2021-002472, https://doi.org/10.1136/jitc-2021-002472
Journal for Immunotherapy of Cancer
BackgroundImmune checkpoint inhibitors have revolutionized cancer treatment, but the benefits in refractory patients with esophageal cancer have been modest. Predictors of response as well as new targets for novel therapeutic combinations are needed.
Autor:
Sharon Ng, Meenal Sinha, Rahul Aggarwal, Terence W. Friedlander, Christopher Nguyen, Li Zhang, Sumit K. Subudhi, Brandon Chen, E Liu, Alexander Cheung, Padmanee Sharma, Kate Allaire, James P. Allison, Lawrence Fong, Matthew H. Spitzer, Eric J. Small, Jaqueline Marquez
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 5
BackgroundSipuleucel-T is a US Food and Drug Administration-approved autologous cellular immunotherapy that improves survival in patients with metastatic castration-resistant prostate cancer (mCRPC). We examined whether administering ipilimumab after
Autor:
Calum MacAulay, Erin A. Marshall, John C. English, Sonia H. Y. Kung, Katey S. S. Enfield, Stephen Lam, Spencer D. Martin, Zhaoyang Chen, Paul Gallagher, Brad H. Nelson, Katy Milne, Martial Guillaud, Wan L. Lam
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-13 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background The tumor microenvironment (TME) is a complex mixture of tumor epithelium, stroma and immune cells, and the immune component of the TME is highly prognostic for tumor progression and patient outcome. In lung cancer, anti-PD-1 therapy signi
Autor:
Magali Svrcek, Quentin Letourneur, Toky Ratovomanana, Adrien Buisson, Anna Pellat, François Paye, Lucile Armenoult, Christelle De La Fouchardiere, Thierry André, Romain Cohen, Alex Duval, Mira Ayadi, Matthieu Sarabi, Vincent Jonchère, Pierre Meeus, Raphael Colle
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 2 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2021, 9 (2), pp.e001903. ⟨10.1136/jitc-2020-001903⟩
Metastatic colorectal cancers (mCRC) harboring microsatellite instability (MSI) are sensitive to immune checkpoint inhibitors (ICIs), but the mechanisms of resistance to ICIs remain unclear. Dissociated responses in patients with ICI-treated cancer s
Autor:
Priti Hegde, Shakti H. Ramkissoon, Lajos Pusztai, Kim Blenman, Brian M. Alexander, Natalie Danziger, Richard S.P. Huang, Jeffrey S. Ross, David L. Rimm, Mariya Rozenblit
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Programmed Death Ligand 1 (PD-L1) positivity rates differ between different metastatic sites and the primary tumor. Understanding PD-L1 expression characteristics could guide biopsy procedures and motivate research to better understand site-specific
Autor:
Fatima Karzai, Beatriz Walter-Rodriguez, Houssein Abdul Sater, Marijo Bilusic, Jennifer L. Marte, Seth M. Steinberg, Renee N. Donahue, James L. Gulley, Christopher R. Heery, William L. Dahut, Guinevere Chun, Peter A. Pinto, Ravi A. Madan, Ismail B. Turkbey, Lisa M. Cordes, Stephanie Harmon, Peter L. Choyke, Jeffrey Schlom
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
BackgroundClinical trials have shown the ability of therapeutic vaccines to generate immune responses to tumor-associated antigens (TAAs). What is relatively less known is if this translates into immune-cell (IC) infiltration into the tumor microenvi
Autor:
Yangyang Qi, Zhaopei Liu, Yu Zhu, Quan Zhou, Jiajun Wang, Jianming Guo, Qiuren Huang, Yiwei Wang, Hongyu Zhang, Han Zeng, Yu Xia, Zewei Wang, Le Xu, Qi Bai, Jiejie Xu, Li Liu, Ying Xiong, Bo Dai, Yuan Chang, Weijuan Zhang
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundPatients with BRCA1-associated protein 1 (BAP1)-mutant clear cell renal cell carcinoma (ccRCC) have worse prognosis. C-C chemokine receptor 5 (CCR5) plays an important role in ccRCC development and its expression is elevated in BAP1-mutant